1. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial;Richman, D.D.; Fischl, M.A.; Grieco, M.H.;NEnglJMed,1987
2. The combined toxicity of azidothymidine and antimycobacterial agents. A retrospective study;Kavesh, M.G.; Holzman, R.S.; Seidlin, M.;Am Rev Respir Dis; Currently zidovudine is recommended for persons who have clinical evidence of immunosuppression or who have CD4+ counts of 0-2 x 109/l or less, and preliminary data indicate benefit for those with counts of 04-045 x 109/1. This is a rapidly evolving area, however, and recommendations are likely to be changing in the near future,1989
3. Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: pathophysiology, therapy and prevention;Montgomery, A.B.;Sem Respir Inf,1989
4. Prognosis and natural history of Pneumocystis carinii pneumonia: indicators for early and late survival;Rainer, C.A.; Feigal, D.W.; Leoung, G.S.; Clement, M.; Wofsy, C.;Abstracts III Internat ConfAIDS
5. Successful References chemoprophylaxis for Pneumocystis carinii pneumonitis;Hughes, W.T.; Kuhn, S.; Chaudhary, S.;N Engl J Med,1977